OXIS International, Inc. (OTCMKTS:OXIS) subsidiary appreciated the “cancer moonshot,” which intends to encourage cooperation between the private sector and the government in the advancement of new treatments for cancer.
Recently in an article, former NY Mayor Michael R. and VP Biden, highlighted the moonshot as a measure to identify a cure for cancer by backing the same “American ingenuity” that led humankind to the moon. Biden mentioned that they are of view that it is time for a complete and full national commitment to free the globe of this disease. He added that ending cancer as the world knows is finally within the grasp of medical world, and OXIS Biotech is delighted to be part of that successful efforts.
OXIS subsidiary boasts a strong portfolio of next-gen cancer measure, the type the “cancer moonshot” is focused on. The lead drug candidate of company, named as OXS-1550, is in Phase I/Phase II clinical study as a cure for leukemia and non-Hodgkins lymphoma. It is a bispecific immunotherapy advanced to hunt cancer cells and destroy them, without bringing any harm to healthy cells.
Another news that was making buzz during same time as that of OXIS subsidiary was related with Juno Therapeutics Inc (NASDAQ:JUNO). A large percentage of the smart CAR-T investors were aware that an impediment like the U.S. clinical hold levied on Juno was in horizon. However, what delighted the market is how quickly the issue was resolved.
The FDA is content that the issue can be laid evenly at company’s fludarabine-containing lymphodepleting treatment, and has been set to perform in record time to bring the show back on the track. Neurotoxicity will persist to dog CAR-T, however, like the cytokine release issues that led to Juno’s 2014 clinical hold, it appears like a storm in a teacup. This development not only means relief to Juno but it extends beyond the firm to other CAR-T players in the industry.